UBS Group’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

UBS Group’s Portfolio ORIAU Stock Details ORIAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-127	Closed	-$1.24K	–	11186
2022 Q4	$1.24K	Hold	127	–	–	﹤0.01%	9911
2022 Q3	$1K	Hold	127	–	–	﹤0.01%	10191
2022 Q2	$1K	Hold	127	–	–	﹤0.01%	10116
2022 Q1	$1K	Hold	127	–	–	﹤0.01%	10049
2021 Q4	$1K	Buy	+127	New	+$1.26K	﹤0.01%	10119

Other funds holding ORIAU

JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group's ORIAU Position: Q1 2023 in Review

UBS Group sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q1 2023, closing a stake of 127 shares — an estimated $1.24K sold.

UBS Group first reported a position in ORIAU in Q4 2021 and held it in 5 quarters. The position peaked at $1.24K in Q4 2022. 4 funds tracked by Wall St. Rank hold ORIAU as of Q1 2023.

UBS Group reported no remaining Orion Biotech Opportunities Corp. Units position as of Q1 2023 after selling out during the quarter.
UBS Group sold 127 Orion Biotech Opportunities Corp. Units shares in Q1 2023, an estimated $1.24K.
UBS Group first reported a position in Orion Biotech Opportunities Corp. Units in Q4 2021 and held it in 5 quarters.
UBS Group's Orion Biotech Opportunities Corp. Units position peaked at $1.24K in Q4 2022.
4 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.